As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) in Q1 CY2025, with sales flat year on year at $6.67 billion. The ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...